Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Accumulated Expenses (2019 - 2026)

Atea Pharmaceuticals' Accumulated Expenses history spans 8 years, with the latest figure at $2.3 million for Q1 2026.

  • Quarterly Accumulated Expenses fell 20.15% to $2.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Mar 2026, down 20.15% year-over-year, with the annual reading at $6.4 million for FY2025, 9.04% up from the prior year.
  • Accumulated Expenses came in at $2.3 million for Q1 2026, down from $6.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $20.4 million in Q2 2024 to a low of $1.9 million in Q1 2022.
  • The 5-year median for Accumulated Expenses is $6.4 million (2025), against an average of $9.7 million.
  • Year-over-year, Accumulated Expenses plummeted 91.53% in 2022 and then surged 471.11% in 2023.
  • Atea Pharmaceuticals' Accumulated Expenses stood at $15.2 million in 2022, then crashed by 62.54% to $5.7 million in 2023, then rose by 3.65% to $5.9 million in 2024, then grew by 9.04% to $6.4 million in 2025, then tumbled by 64.68% to $2.3 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Accumulated Expenses are $2.3 million (Q1 2026), $6.4 million (Q4 2025), and $4.9 million (Q3 2025).